JP2016536361A5 - - Google Patents

Download PDF

Info

Publication number
JP2016536361A5
JP2016536361A5 JP2016551017A JP2016551017A JP2016536361A5 JP 2016536361 A5 JP2016536361 A5 JP 2016536361A5 JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016551017 A JP2016551017 A JP 2016551017A JP 2016536361 A5 JP2016536361 A5 JP 2016536361A5
Authority
JP
Japan
Prior art keywords
seq
antibody
hours
administration
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536361A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/073612 external-priority patent/WO2015067570A2/en
Publication of JP2016536361A publication Critical patent/JP2016536361A/ja
Publication of JP2016536361A5 publication Critical patent/JP2016536361A5/ja
Pending legal-status Critical Current

Links

JP2016551017A 2013-11-06 2014-11-03 Cd33抗体及び脱メチル剤を含む医薬配合物 Pending JP2016536361A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191839 2013-11-06
EP13191839.3 2013-11-06
PCT/EP2014/073612 WO2015067570A2 (en) 2013-11-06 2014-11-03 Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents

Publications (2)

Publication Number Publication Date
JP2016536361A JP2016536361A (ja) 2016-11-24
JP2016536361A5 true JP2016536361A5 (enExample) 2017-12-14

Family

ID=49518850

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551017A Pending JP2016536361A (ja) 2013-11-06 2014-11-03 Cd33抗体及び脱メチル剤を含む医薬配合物

Country Status (4)

Country Link
US (2) US20150125447A1 (enExample)
EP (1) EP3066125A2 (enExample)
JP (1) JP2016536361A (enExample)
WO (1) WO2015067570A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
EP3191187B1 (en) 2014-09-09 2021-07-28 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
JP6802791B2 (ja) 2014-12-04 2020-12-23 ヤンセン バイオテツク,インコーポレーテツド 急性骨髄性白血病の治療のための抗cd38抗体
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
NZ777133A (en) 2015-06-22 2025-05-02 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PE20181090A1 (es) * 2015-06-24 2018-07-09 Janssen Biotech Inc Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
CN116059219A (zh) * 2015-07-16 2023-05-05 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MD3827845T2 (ro) 2015-11-03 2022-09-30 Janssen Biotech Inc Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US11830602B2 (en) 2020-10-02 2023-11-28 Cilag Gmbh International Surgical hub having variable interconnectivity capabilities
US12213801B2 (en) 2020-10-02 2025-02-04 Cilag Gmbh International Surgical visualization and particle trend analysis system
US11672534B2 (en) 2020-10-02 2023-06-13 Cilag Gmbh International Communication capability of a smart stapler
US11963683B2 (en) 2020-10-02 2024-04-23 Cilag Gmbh International Method for operating tiered operation modes in a surgical system
US11748924B2 (en) 2020-10-02 2023-09-05 Cilag Gmbh International Tiered system display control based on capacity and user operation
US12580072B2 (en) 2020-10-02 2026-03-17 Cilag Gmbh International Cloud analytics packages
US11992372B2 (en) 2020-10-02 2024-05-28 Cilag Gmbh International Cooperative surgical displays
US12064293B2 (en) 2020-10-02 2024-08-20 Cilag Gmbh International Field programmable surgical visualization system
US12016566B2 (en) 2020-10-02 2024-06-25 Cilag Gmbh International Surgical instrument with adaptive function controls
US12472032B2 (en) 2020-10-02 2025-11-18 Cilag Gmbh International Monitoring of user visual gaze to control which display system displays the primary information
US11877897B2 (en) 2020-10-02 2024-01-23 Cilag Gmbh International Situational awareness of instruments location and individualization of users to control displays
US12484897B2 (en) 2020-10-02 2025-12-02 Cilag Gmbh International Surgical instrument with adaptive configuration control
CN116948029A (zh) 2022-04-20 2023-10-27 南京融捷康生物科技有限公司 一种包含IgG类Fc区变体的抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
UA112062C2 (uk) * 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент

Similar Documents

Publication Publication Date Title
JP2016536361A5 (enExample)
AU2013327116B2 (en) Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
JP2015534579A5 (enExample)
JP2015532292A5 (enExample)
JP2014533279A5 (enExample)
JP2017507652A5 (enExample)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2018534933A5 (enExample)
JP2016094424A5 (enExample)
JP2016507470A5 (enExample)
RU2018123717A (ru) Комбинированные лечения, их применения и способы
JP2010520290A5 (enExample)
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
JP2011046732A5 (enExample)
JP2017528476A5 (enExample)
JP2015534580A5 (enExample)
RU2018145852A (ru) Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение
JP2014205674A5 (enExample)
JP2016502504A5 (enExample)
JP2014530215A5 (enExample)
FI3805268T3 (fi) Vasta-aine joka sitoo ErbB-2:ta ja ErbB-3:a
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2013529183A5 (enExample)
JP2015529225A5 (enExample)
JP2009505676A5 (enExample)